Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.
Scherrer AU, von Wyl V, Fux CA, Opravil M, Bucher HC, Fayet A, Decosterd LA, Hirschel B, Khanlari B, Yerly S, Klimkait T, Furrer H, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. Scherrer AU, et al. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):464-71. doi: 10.1097/QAI.0b013e3181bca4ec. J Acquir Immune Defic Syndr. 2010. PMID: 19841590
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors.
Scherrer AU, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Garzoni C, Hirschel B, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Günthard HF; Swiss HIV Cohort Study (SHCS). Scherrer AU, et al. J Acquir Immune Defic Syndr. 2011 May 1;57(1):24-31. doi: 10.1097/QAI.0b013e318211925e. J Acquir Immune Defic Syndr. 2011. PMID: 21283013
Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.
Scherrer AU, von Wyl V, Joos B, Klimkait T, Bürgisser P, Yerly S, Böni J, Ledergerber B, Günthard HF; Swiss HIV Cohort Study. Scherrer AU, et al. J Infect Dis. 2011 Mar 15;203(6):791-7. doi: 10.1093/infdis/jiq130. Epub 2011 Feb 1. J Infect Dis. 2011. PMID: 21285456 Free PMC article.
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.
Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Günthard HF; Swiss HIV Cohort Study. Scherrer AU, et al. Clin Infect Dis. 2011 Dec;53(11):1143-52. doi: 10.1093/cid/cir669. Epub 2011 Oct 13. Clin Infect Dis. 2011. PMID: 21998284 Free article.
Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection.
Schüpbach J, Bisset LR, Gebhardt MD, Regenass S, Bürgisser P, Gorgievski M, Klimkait T, Andreutti C, Martinetti G, Niederhauser C, Yerly S, Pfister S, Schultze D, Brandenberger M, Schöni-Affolter F, Scherrer AU, Günthard HF; Swiss HIV Cohort Study. Schüpbach J, et al. Among authors: scherrer au. BMC Infect Dis. 2012 Apr 12;12:88. doi: 10.1186/1471-2334-12-88. BMC Infect Dis. 2012. PMID: 22497961 Free PMC article.
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Cellerai C, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Günthard HF; Swiss HIV Cohort Study. Scherrer AU, et al. PLoS One. 2012;7(6):e37983. doi: 10.1371/journal.pone.0037983. Epub 2012 Jun 18. PLoS One. 2012. PMID: 22719859 Free PMC article.
131 results